Haemonetics Corporation (HAE) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-10.2%

$108.76

vs $121.06 price

Levered DCF

$93.24

After debt service

Piotroski score

8 / 9

Strong

Altman Z-score

3.38

Safe zone

Rating

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
P/E	26.36×	19.09×	36.55×	36.45×	74.38×	70.71×	66×	83.88×
P/B	3.2×	3.87×	4.48×	5.14×	4.31×	7.69×	8.6×	6.93×
P/S	1.91×	2.34×	3.28×	3.6×	3.25×	6.46×	5.11×	4.78×
EV / EBITDA	13.14×	11.3×	16.21×	17.98×	18.47×	33.7×	19.41×	24.91×
Gross margin	55.7%	57.2%	54.4%	53.3%	53.4%	49.2%	49.4%	43.2%
Operating margin	18.1%	16.3%	12.6%	13.4%	8.1%	10.3%	10.5%	8.6%
Net margin	7.3%	12.3%	9.0%	9.9%	4.4%	9.1%	7.7%	5.7%
Current ratio	2.95×	1.62×	2.56×	3.06×	1.71×	2.74×	2.2×	2.44×
Debt / equity	1.54×	1.49×	0.84×	0.94×	1.04×	1.06×	0.75×	0.52×
Interest coverage	8.41×	22.76×	12.67×	10.67×	4.72×	5.33×	6.38×	8.43×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2026	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Return on equity	12.2%	20.4%	12.2%	14.1%	5.8%	10.9%	13.0%	8.2%
Return on invested capital	8.7%	8.1%	6.7%	7.5%	3.4%	5.6%	8.4%	5.9%
Return on assets	4.1%	6.8%	5.4%	6.0%	2.3%	4.4%	6.0%	4.3%
Free cash flow yield	10.2%	4.5%	3.3%	3.9%	2.3%	1.3%	2.2%	0.9%
Earnings yield	3.8%	5.3%	2.7%	2.7%	1.3%	1.4%	1.5%	1.2%
Enterprise value	$3.5B	$4.1B	$4.9B	$4.7B	$3.7B	$6.2B	$5.4B	$4.8B
Net debt / EBITDA	3.65×	2.53×	2.07×	1.85×	2.57×	3.18×	1.1×	0.94×
Cash conversion cycle (days)	217	241	207	187	244	278	221	157